Valuation: Insmed Incorporated

Market Cap 28.89B 25.03B 23.45B 21.39B 40.21B 2,755B 40.83B 276B 108B 1,380B 108B 106B 4,600B P/E 2026 *
-86.5x
P/E 2027 * 118x
Enterprise Value 28.26B 24.48B 22.94B 20.92B 39.33B 2,695B 39.94B 270B 105B 1,349B 106B 104B 4,500B EV / Sales 2026 *
15.7x
EV / Sales 2027 * 9.58x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day-0.22%
1 week+33.59%
Current month+34.16%
1 month+14.42%
3 months+14.03%
6 months-9.50%
Current year-23.99%
1 week 126.44
Extreme 126.44
135.5
1 month 96.42
Extreme 96.42
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.21
Extreme 21.21
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
8/6/26 Fiscal year

Chief Technology Officer

81,519 0.0376%
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%+33.59%+8.43%+489.75% 28.95B
-0.73%+7.82%+73.81%+102.34% 70.51B
+1.60%+1.66%+37.76%+67.36% 54.05B
-0.79%+9.86%+47.60%+6.84% 24.05B
-0.06%+0.61%-16.45%-13.26% 23.31B
-1.37%+7.87%+251.71%+464.53% 18.67B
+2.21%+7.66%+47.18%-20.09% 18.37B
0.00%+3.94%+26.20%+623.29% 16.1B
-1.85%-11.15%+32.75%+134.11% 12.72B
-2.23%+0.39%+390.17%+202.43% 12.61B
Average -0.33%+7.76%+89.92%+205.73% 27.93B
Weighted average by Cap. -0.08%+9.17%+70.07%+170.00%

Financials

2026 *2027 *
Net sales 1.8B 1.56B 1.46B 1.34B 2.51B 172B 2.55B 17.23B 6.74B 86.19B 6.78B 6.63B 287B 2.89B 2.51B 2.35B 2.14B 4.03B 276B 4.09B 27.64B 10.8B 138B 10.87B 10.63B 461B
Net income -326M -283M -265M -241M -454M -31.1B -461M -3.11B -1.22B -15.57B -1.22B -1.2B -51.93B 233M 202M 189M 173M 324M 22.22B 329M 2.22B 870M 11.13B 875M 856M 37.1B
Net Debt -632M -547M -513M -468M -879M -60.26B -893M -6.03B -2.36B -30.17B -2.37B -2.32B -101B -1.16B -1B -939M -856M -1.61B -110B -1.63B -11.04B -4.32B -55.24B -4.34B -4.25B -184B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-08-12 US$132.28 -0.22% 1,563,223
26-08-11 US$132.57 -1.62% 2,728,711
26-08-10 US$134.75 +2.78% 3,630,056
26-08-07 US$131.10 -1.09% 4,904,624
26-08-06 US$132.55 +33.86% 12,036,146
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
132.28USD
Average target price
200.05USD
Spread / Average Target
+51.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock